|
1
|
Modlin IM, Pavel M, Kidd M and Gustafsson
BI: Review article somatostatin analogues in the treatment of
gastroenteropancreatic neuroendocrine (carcinoid) tumours. Aliment
Pharmacol Ther. 31:169–188. 2010.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Krenning EP, Kwekkeboom DJ, Bakker WH,
Breeman WA, Kooij PP, Oei HY, van Hagen M, Postema PT, de Jong M,
Reubi JC, et al: Somatostatin receptor scintigraphy with
[111In-DTPA-D-Phe1]- and [123l-Tyr3]-octreotide: The Rotterdam
experience with more than 1000 patients. Eur J Nucl Med.
20:716–731. 1993.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Nilsson O, Kolby L, Wangberg B, Wigander
A, Billig H, William-Olsson L, Fjälling M, Forssell-Aronsson E and
Ahlman H: Comparative studies on the expression of somatostatin
receptor subtypes, outcome of octreotide scintigraphy and response
to octreotide treatment in patients with carcinoid tumours. Br J
Cancer. 77:632–637. 1998.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Bruns C, Lewis I, Briner U, Meno-Tetang G
and Weckbecker G: SOM230: A novel somatostatin peptidomimetic with
broad somatotropin release inhibiting factor (SRIF) receptor
binding and a unique antisecretory profile. Eur J Endocrinol.
146:707–716. 2002.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Reubi JC, Kvols LK, Waser B, Nagorney DM,
Heitz PU, Charboneau JW, Reading CC and Moertel C: Detection of
somatostatin receptors in surgical and percutaneous needle biopsy
samples of carcinoids and islet cell carcinomas. Cancer Res.
50:5969–5977. 1990.PubMed/NCBI
|
|
6
|
Aparicio T, Ducreux M, Baudin E, Sabourin
JC, De Baere T, Mitry E, Schlumberger M and Rougier P: Antitumour
activity of somatostatin analogues in progressive metastatic
neuroendocrine tumours. Eur J Cancer. 37:1014–1019. 2001.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Ducreux M, Ruszniewski P, Chayvialle JA,
Blumberg J, Cloarec D, Michel H, Raymond JM, Dupas JL, Gouerou H,
Jian R, et al: The antitumoral effect of the long-acting
somatostatin analog lanreotide in neuroendocrine tumors. Am J
Gastroenterol. 95:3276–3281. 2000.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Eriksson B and Oberg K: Summing up 15
years of somatostatin analog therapy in neuroendocrine tumours:
Future outlook. Ann Oncol. 10 (Suppl 2):S31–S38. 1999.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Ricci S, Antonuzzo A, Galli L, Ferdeghini
M, Bodei L, Orlandini C and Conte PF: Octreotide acetate
long-acting release in patients with metastatic neuroendocrine
tumours pretreated with lanreotide. Ann Oncol. 11:1127–1130.
2000.
|
|
10
|
Kolby L, Persson G, Franzen S and Ahrén B:
Randomized clinical trial of the effect of interferon alpha on
survival in patients with disseminated midgut carcinoid tumours. Br
J Surg. 90:687–693. 2003.PubMed/NCBI View
Article : Google Scholar
|
|
11
|
Faiss S, Pape UF, Bohmig M, Dörffel Y,
Mansmann U, Golder W, Riecken EO and Wiedenmann B: International
Lanreotide and Interferon Alfa Study Group: Prospective,
randomized, multicentre trial on the antiproliferative effect of
lanreotide, interferon alfa, and their combination for therapy of
metastatic neuroendocrine gastroenteropancreatic tumors-the
International Lanroetid and Interferon Alfa Study Group. J Clin
Oncol. 21:2689–2696. 2003.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Arnold R, Rinke A, Klose KJ, Müller HH,
Wied M, Zamzow K, Schmidt C, Schade-Brittinger C, Barth P, Moll R,
et al: Octreotide versus octreotide plus interferon-alpha in
endocrine gastroenteropancreatic tumors: A randomized trial. Clin
Gastroenterol Hepatol. 3:761–771. 2005.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Rinke A, Muller HH, Schade-Brittinger C,
Klose KJ, Barth P, Wied M, Mayer C, Aminossadati B, Pape UF, Bläker
M, et al: Placebo-controlled, double-blind, prospective, randomized
study on the effect of octreotide LAR in the control of tumour
growth in patients with metastatic neuroendocrine midgut tumours: A
report from the PROMID Study Group. J Clin Oncol. 27:4656–4663.
2009.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Caplin ME, Pavel M, Ćwikła JB, Phan AT,
Raderer M, Sedláčková E, Cadiot G, Wolin EM, Capdevila J, Wall L,
et al: Anti-tumour effects of lanreotide for pancreatic and
intestinal neuroendocrine tumours: The CLARINET open-label
extension study. Endocr Relat Cancer. 23:191–199. 2016.PubMed/NCBI View Article : Google Scholar
|
|
15
|
O'Toole D, Savenau A, Couvelard A, Gunz G,
Enjalbert A, Jaquet P, Ruszniewski P and Barlier A: The analysis of
quantitative expression of somatostatin and dopamine receptors in
gastro-entero-pancreatic tumours opens new therapeutic strategies.
Eur J Endocrinol. 155:849–857. 2006.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Florio T, Barbieri F, Spaziante R, Zona G,
Hofland LJ, van Koetsveld PM, Feelders RA, Stalla GK,
Theodoropoulou M, Culler MD, et al: Efficacy of a
dopamine-somatostatin chimeric molecule, BIM-23A760, in the control
of cell growth from primary cultures of human non-functioning
pituitary adenomas: A multi-center study. Endocr Relat Cancer.
15:583–596. 2008.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Kidd M, Drozdov I, Joseph R, Pfragner R,
Culler M and Modlin I: Differential cytotoxicity of novel
somatostatin and dopamine chimeric compounds on bronchopulmonary
and small intestinal neuroendocrine tumor cell lines. Cancer.
113:690–700. 2008.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Shah T and Caplin M: Endocrine tumours of
the gastrointestinal tract. Biotherapy for metastatic endocrine
tumours. Best Pract Res Clin Gastroenterol. 19:617–636.
2005.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Oberg K: Interferon in the management of
neuroendocrine GEP-tumors: A review. Digestion. 62 (Suppl
1):S92–S97. 2000.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Dahan L, Bonnetain F, Rougier P, Raoul JL,
Gamelin E, Etienne PL, Cadiot G, Mitry E, Smith D, Cvitkovic F, et
al: Phase III trial of chemotherapy using 5-fluorouracil and
streptozocin compared with interferon alpha for advanced carcinoid
tumours: FNCLCC-FFCD 97101. Endocr Relat Cancer. 16:1351–1361.
2009.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Yao JC, Lombard-Bohas C, Baudin E, Kvols
LK, Rougier P, Ruszniewski P, Hoosen S, St Peter J, Haas T, Lebwohl
D, et al: Daily oral everolimus activity in patients with
metastatic pancreatic neuroendocrine tumors after failure of
cytotoxic chemotherapy a phase II trial. J Clin Oncol. 28:69–76.
2010.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Rindi G, Kloppel G, Alhman H, Caplin M,
Couvelard A, de Herder WW, Erikssson B, Falchetti A, Falconi M,
Komminoth P, et al: TNM staging of foregut (neuro)endocrine tumors:
A consensus proposal including a grading system. Virchows Arch.
449:395–401. 2006.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Hentic O, Couvelrand A, Rebours V, Zappa
M, Dokmak S, Hammel P, Maire F, O'Toole D, Lévy P, Sauvanet A and
Ruszniewski P: Ki-67 index, tumor differentiation, and extent of
liver involvement are independent prognostic factors in patients
with liver metastases of digestive endocrine carcinomas. Endocr
Relat Cancer. 18:51–59. 2010.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Couverald A, Deschamps L, Ravaud P, Baron
G, Sauvanet A, Hentic O, Colnot N, Paradis V, Belghiti J, Bedossa P
and Ruszniewski P: Heterogeneity of tumor prognostic markers: A
reproducibility study applied to liver metastases of pancreatic
endocrine tumors. Mod Pathol. 22:273–281. 2009.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Klimstra DS, Modlin IR, Adsay NV, Chetty
R, Deshpande V, Gönen M, Jensen RT, Kidd M, Kulke MH, Lloyd RV, et
al: Pathology reporting of neuroendocrine tumors: Application of
the Delphic consensus process to the development of a minimum
pathology data set. Am J Surg Pathol. 34:300–313. 2010.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Kulke MH, Hornick JL, Frauenhoffer C,
Hooshmand S, Ryan DP, Enzinger PC, Meyerhardt JA, Clark JW, Stuart
K, Fuchs CS and Redston MS: O6-methylguanine DNA methyltransferase
deficiency and response to temozolomide-based therapy in patients
with neuroendocrine tumors. Clin Cancer Res. 15:338–345.
2009.PubMed/NCBI View Article : Google Scholar
|
|
27
|
O'Toole D, Couverlard A, Rebours V, Zappa
M, Hentic O, Hammel P, Levy P, Bedossa P, Raymond E and Ruszniewski
P: Molecular markers associated with response to chemotherapy in
gastro-entero-pancreatic neuroendocrine tumors. Endocr Relat
Cancer. 17:847–856. 2010.PubMed/NCBI View Article : Google Scholar
|
|
28
|
McEntee GP, Nagorney DM, Kvols LK, Moertel
CG and Grant CS: Cytoreductive hepatic surgery for neuroendocrine
tumors. Surgery. 108:1091–1096. 1990.PubMed/NCBI
|
|
29
|
Moertel CG, Lavin PT and Hahn RG: Phase II
trial of doxorubicin therapy for advanced islet cell carcinoma.
Cancer Treat Rep. 66:1567–1569. 1982.PubMed/NCBI
|
|
30
|
Moertel CG, Lefkopoulo M, Lipsitz S, Hahn
RG and Klaassen D: Streptozocin-doxorubicin,
streptozocin-fluorouracil or chlorozotocin in the treatment of
advanced islet-cell carcinoma. N Eng J Med. 326:519–523.
1992.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Eriksson B, Skogseid B, Lundqvist G, Wide
L, Wilander E and Oberg K: Medical treatment and long-term survival
in a prospective study of 84 patients with endocrine pancreatic
tumors. Cancer. 65:1883–1890. 1990.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Delaunoid T, Decreux M, Boige V, Dromain
C, Sabourin JC, Duvillard P, Schlumberger M, de Baere T, Rougier P,
Ruffie P, et al: The doxorubicin-streptozocin combination for the
treatment of advanced well-differentiated pancreatic endocrine
carcinoma; A judicious option? Eur J Cancer. 40:515–520.
2004.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Fjallskog ML, Janson ET, Falkmer UG, Vatn
MH, Oberg KE and Eriksson BK: Treatment with combined streptozocin
and liposomal doxorubicin in metastatic endocrine pancreatic
tumors. Neuroendocrinology. 88:53–58. 2008.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Bajetta E, Catena L, Procopio G, De Dosso
S, Bichisao E, Ferrari L, Martinetti A, Platania M, Verzoni E,
Formisano B and Bajetta R: Are capecitabine and oxaliplatin (XELOX)
suitable treatments for progressing low-grade and high-grade
neuroendocrine tumours? Cancer Chemother Pharmacol. 59:637–642.
2007.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Cassier PA, Walter T, Eymard B, Ardisson
P, Perol M, Paillet C, Chayvialle JA, Scoazec JY, Hervieu V and
Bohas CL: Gemcitabine and oxaliplatin combination chemotherapy for
metastatic well-differentiated neuroendocrine carcinomas a
single-center experience. Cancer. 115:3392–3399. 2009.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Ramanathan RK, Cnaan A, Hahn RG, Carbone
PP and Haller DG: Phase II trial dacarbazine (DTIC) in advanced
pancreatic islet cell carcinoma. Study of the Eastern Cooperative
Oncology Group-E6282. Ann Oncol. 12:1139–1143. 2001.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Vera K, Djafari L, Faivre S, Guillamo JS,
Djazouli K, Osorio M, Parker F, Cioloca C, Abdulkarim B, Armand JP
and Raymond E: Dose-dense regimen of temozolomide given every other
week in patients with primary central nervous system tumors. Ann
Oncol. 15:161–171. 2004.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Strosberg JR, Fine RL, Choi J, Nasir A,
Coppola D, Chen DT, Helm J and Kvols L: First-line chemotherapy
with capecitabine and temozolomide in patients with metastatic
pancreatic endocrine carcinomas. Cancer. 117:268–275.
2011.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Di Bartolomeo M, Bajetta E, Bochicchio AM,
Carnaghi C, Somma L, Mazzaferro V, Visini M, Gebbia V, Tumolo S and
Ballatore P: A phase II trial of dacarbazine, fluorouracil and
epirubicin in patients with neuroendocrine tumours. A study by the
Italian Trials in Medical Oncology (I.T.M.O.) Group. Ann Oncol.
6:77–79. 1995.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Frame J, Kelsen D, Kemeny N, Cheng E,
Niedzwiecki D, Heelan R and Lippermann R: A phase II trial of
streptozocin and Adriamycin in advanced APUD tumors. Am J Clin
Oncol. 11:490–495. 1998.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Sun W, Lipsitz S, Catalano P, Mailliard JA
and Haller DG: Eastern Cooperative Oncology Group: Phase II/III
study of doxorubicin with fluorouracil compared with streptozocin
with fluorouracil or dacarbazine in the treatment of advanced
carcinoid tumors: Eastern Cooperative Oncology Group Study E1281. J
Clin Oncol. 23:4897–4904. 2005.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Eriksson B, Kloppel G, Krenning E, Ahlman
H, Plöckinger U, Wiedenmann B, Arnold R, Auernhammer C, Körner M,
Rindi G and Wildi S: Frascati Consensus Conference participants:
Consensus guidelines for the management of patients with digestive
neuroendocrine tumors-well-differentiated jejunal-ileal
tumor/carcinoma. Neuroendocrinology. 87:8–19. 2008.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Yao JC, Phan A, Hoff PM, Chen HX,
Charnsangavej C, Yeung SC, Hess K, Ng C, Abbruzzese JL and Ajani
JA: Targeting vascular endothelial growth factor in advanced
carcinoid tumor: A random assignment phase II study of depot
octreotide with bevacizumab and pegylated interferon alpha-2b. J
Clin Oncol. 26:1316–1323. 2008.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Konno H, Arai T, Tanaka T, Baba M,
Matsumoto K, Kanai T, Nakamura S, Baba S, Naito Y, Sugimura H, et
al: Antitumor effect of a neutralizing antibody to vascular
endothelial growth factor on liver metastasis of endocrine
neoplasm. Jpn J Cancer Res. 89:933–939. 1998.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Zhang J, Jia Z, Li Q, Wang L, Rashid A,
Zhu Z, Evans DB, Vauthey JN, Xie K and Yao JC: Elevated expression
of vascular endothelial growth factor correlates with increased
angiogenesis and decreased progression-free survival among patients
with low-grade neuroendocrine tumors. Cancer. 109:1478–1486.
2007.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Kunz PL, Kuo T, Zahn JM, Kaiser HL, Norton
JA, Longacre BC, Ford JM, Balise RR and Fisher GA: A phase II study
of capecitabine, oxaliplatin, and bevacizumab for metastatic or
unresectable neuroendocrine tumors. J Clin Oncol. 28 (Suppl
15)(S4104)2010.
|
|
47
|
Mitry E, Walter T, Baudin E, Kurtz J-E,
Ruszniewski P, Dominguez-Tinajero S, Bengrine-Lefevre L, Cadiot G,
Dromain C, Farace F, et al: Bevacizumab plus capecitabine in
patients with progressive advanced well-differentiated
neuroendocrine tumors of the gastro-intestinal (GI-NETs) tract
(BETTER trial) – A phase II non-randomised trial. Eur J Cancer.
18:3107–3115. 2014.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Hobday TJ, Rubin J, Holen K, Picus J,
Donehower R, Maples RM, Lloyd R, Mahoney M and Erlichman C: MC044h,
a phase II trial of sorafenib in patients (pts) with metastatic
neuroendocrine tumors (NET) A Phase II Consortium (P2C) study. J
Clin Oncol. 25 (Suppl 18)(S4504)2007.
|
|
49
|
Phan AT, Yao JC, Fogelman DR, Hess KR, Ng
CS, Malinowski SA, Regan E and Kulke M: Prospective,
multi-institutional phase II study of GW786034 (pazopanib) and
depot octreotide (sandostatin LAR) in advanced low-grade
neuroendocrine carcinoma (LGNEC). J Clin Oncol. 28 (Suppl
15)(S4001)2010.
|
|
50
|
Raymond E, Faivre S, Hammel P and
Ruszniewski P: Sunitinib paves the way for targeted therapies in
neuroendocrine tumors. Target Oncol. 4:253–254. 2009.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Kulke MH, Lenz HJ, Meropol NJ, Posey J,
Ryan DP, Picus J, Bergsland E, Stuart K, Tye L, Huang X, et al:
Activity of sunitinib in patients with advanced neuroendocrine
tumors. J Clin Oncol. 26:3403–3410. 2008.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Raymond E, Dahan L, Raoul JL, Bang YJ,
Borbath I, Lombard-Bohas C, Valle J, Metrakos P, Smith D, Vinik A,
et al: Sunitinib malate for the treatment of pancreatic
neuroendocrine tumors. N Eng J Med. 364:501–513. 2011.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Moreno A, Akcakanat A, Munsell MF, Soni A,
Yao JC and Meric-Bernstam F: Antitumor activity of rapamycin and
octreotide as single agents or in combination in neuroendocrine
tumors. Endocr Relat Cancer. 15:257–266. 2008.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Yao JC, Phan AT, Chang DZ, Wolff RA, Hess
K, Gupta S, Jacobs C, Mares JE, Landgraf AN, Rashid A and
Meric-Bernstam F: Efficacy of RAD001 (everolimus) and octreotide
LAR in advanced low- to intermediate-grade neuroendocrine tumors:
Results od a phase II study. J Clin Oncol. 26:4311–4318.
2008.PubMed/NCBI View Article : Google Scholar
|
|
55
|
O'Reilly KE, Rojo F, She QB, Solit D,
Mills GB, Smith D, Lane H, Hofmann F, Hicklin DJ, Ludwig DL, et al:
MTor inhibition induces upstream receptor tyrosine kinase
signalling and activates Akt. Cancer Res. 66:1500–1508.
2006.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Yao JC, Shah MM, Ito T, Bohas CL, Wolin
EM, Van Cutsem E, Hobday TJ, Okusaka T, Capdevila J, de Vries EG,
et al: Everolimus for advanced pancreatic neuroendocrine tumors. N
Eng J Med. 364:514–523. 2011.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Yao JC, Hainsworth JD, Baudin E, Peeters
M, Hoersch D, Klimovsky LB, Grouss K, Jehl V and Pavel M:
Everolimus plus octreotide LAR (E+O) versus placebo plus octreotide
LAR (P+O) in patients with advanced neuroendocrine tumors (NET):
Updated results of a randomized, double-blind, placebo-controlled,
multicentre phase III trial (RADIANT-2). J Clin Oncol. 29 (Suppl
4)(S159)2011.
|
|
58
|
Kos-Kudła B, Blicharz-Dorniak J,
Strzelczyk J, Bałdys-Waligórska A, Bednarczuk T, Bolanowski M,
Boratyn-Nowicka A, Borowska M, Cichocki A, Ćwikła JB, et al:
Diagnostic and therapeutic guidelines for gastro-entero-pancreatic
neuroendocrine neoplasms (recommended by the Polish Network of
Neuroendocrine Tumours). Endokrynol Pol. 68:79–110. 2017.PubMed/NCBI View Article : Google Scholar
|
|
59
|
Mitry E, Baudin E, Ducreux M, Sabourin JC,
Rufié P, Aparicio T, Aparicio T, Lasser P, Elias D, Duvillard P, et
al: Treatment of poorly differentiated neuroendocrine tumours with
etoposide and cisplatin. Br J Cancer. 81:1351–1355. 1999.PubMed/NCBI View Article : Google Scholar
|
|
60
|
Seitz J, Perrier H, Giovannini M, Monges
G, Fourdan O, Barrière N and Viens P: Cancers neuroendocrines
anaplasiques avances interet de l'association VP16-CDDP. Bull
Cancer. 82:433–434. 1995.
|
|
61
|
Mitry E and Rougier P: The treatment of
undifferentiated neuroendocrine tumors. Crit Rev Oncol Hematol.
37:47–51. 2001.PubMed/NCBI View Article : Google Scholar
|
